The patent application WO2020008391A1, filed by Pfizer Inc., relates to methods of treating atopic dermatitis and other inflammatory conditions using abrocitinib [1]. The application details specific dosages and administration regimens for abrocitinib, including its use in combination with other treatments [1].
What is Abrocitinib Used For?
Abrocitinib is a Janus kinase 1 (JAK1) inhibitor. It is indicated for the treatment of adults with refractory moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies or when those therapies are not advisable [2]. It works by blocking the signaling pathways that contribute to inflammation and itching in atopic dermatitis [2].
What Does the Patent Application WO2020008391A1 Cover?
The patent application WO2020008391A1 specifically claims methods of treating inflammatory conditions, including atopic dermatitis [1]. It describes regimens for administering abrocitinib, such as oral administration of specific daily doses [1]. The application also covers the use of abrocitinib in combination with other therapeutic agents to manage these conditions [1].
When Does Abrocitinib's Patent Protection End?
Patent protection for abrocitinib, like other pharmaceuticals, is complex and can involve multiple patents covering different aspects of the drug, such as its composition, manufacturing process, and methods of use [3]. DrugPatentWatch.com tracks these patent landscapes, and the expiry dates can vary depending on the jurisdiction and the specific patent [3]. Generally, patents provide market exclusivity for a defined period, after which generic versions may become available.
Who is Developing Abrocitinib?
Abrocitinib is developed by Pfizer Inc. [1]. It is marketed under the brand name Cibinqo® [2].
How Does Abrocitinib Compare to Other Atopic Dermatitis Treatments?
Abrocitinib is a systemic treatment, meaning it works throughout the body, unlike topical creams [2]. As a JAK1 inhibitor, it targets specific inflammatory pathways [2]. Other treatments for moderate-to-severe atopic dermatitis include other oral medications, injectable biologics, and topical corticosteroids [4]. The choice of treatment depends on the severity of the condition, previous treatment responses, and individual patient factors [4].
What are the Potential Side Effects of Abrocitinib?
Common side effects associated with abrocitinib can include upper respiratory tract infections, acne, and increased blood creatine phosphokinase [2]. More serious potential side effects, which are closely monitored, include serious infections, major adverse cardiovascular events, thrombosis, malignancy, and laboratory abnormalities [2].
Can Generic Versions of Abrocitinib Be Developed?
Once the relevant patents expire and regulatory approvals are obtained, generic manufacturers can seek to produce and market generic versions of abrocitinib [3]. This process typically involves demonstrating bioequivalence to the branded drug [3].
Sources:
[1] https://patents.google.com/patent/WO2020008391A1/
[2] https://www.cibinqo.com/
[3] https://drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777433/